The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer [0.03%]
Oluwaferanmi Bello,Olivia Rieur,Neelima Vidula
Oluwaferanmi Bello
Metastatic breast cancer is a heterogeneous disease entity with varying genomic alterations. Mutations may be acquired through tumor evolution under the pressure of treatment. While both tumor tissue genotyping and cell-free DNA (cfDNA)/cir...
Marianna Danielli,Nicole Benfield,Helen R Warren et al.
Marianna Danielli et al.
Pharmacogenomics (PGX) offers a key route to individualizing cardiovascular therapy, with robust evidence now supporting genotype-guided prescribing for commonly prescribed cardiovascular drugs, such as antiplatelets, -beta-blockers, statin...
Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report [0.03%]
G6PD缺乏的儿科肿瘤患者出现急性溶血性贫血和高铁血红蛋白血症的病例报告
Chaja N Klein,Monique H Suijker,Katja M J Heitink-Pollé et al.
Chaja N Klein et al.
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzymatic disorder that is often asymptomatic until exposure to oxidative stress, such as certain medications. Rasburicase, used for tumor lysis ...
CYP2C:TG haplotype in Ecuador and Nicaragua: insights into CYP2C19 genotype-phenotype correlation in context to Mestizo populations [0.03%]
厄瓜多尔和尼加拉瓜的CYP2C:TG单体型：混血人群中与CYP2C19基因型表型关联的新见解
Carla González de la Cruz,Catalina Altamirano-Tinoco,Juan Antonio Villatoro-García et al.
Carla González de la Cruz et al.
Aim: The impact of the CYP2C:TG haplotype on CYP2C19-mediated omeprazole metabolism was evaluated. Patients and methods: CYP2C19 enzyma...
The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress [0.03%]
欧洲药物基因组学和个性化治疗学会（ESPGT）第八届年会
Ron H N van Schaik,Jesse J Swen,Adrián Llerena et al.
Ron H N van Schaik et al.
On November 5-8, 2025, the European Society of Pharmacogenomics and Personalized Therapy (ESPT) organized its 8th biennial congress, this time in Rotterdam, The Netherlands (www.esptcongress.org). The congress aimed to address the current s...
Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine [0.03%]
急性冠状动脉综合征高出血风险患者抗血小板治疗的药理基因组学与精准医学时代的个体化医疗
Nikolaos Michailidis,Myria Pallikarou,Vangelis G Manolopoulos et al.
Nikolaos Michailidis et al.
The management of high-bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) for an acute coronary syndrome (ACS) remains a significant challenge, requiring careful balancing of ischemic prevention and bleeding av...
Hana Al Alshaykh,Emily Cicali,Larisa H Cavallari et al.
Hana Al Alshaykh et al.
Aim: Assess the acceptance of genotype-based pharmacist recommendations made within a pharmacogenetics (PGx) clinic. Methods: Patients ...
Influence of transporter polymorphisms on digoxin serum concentrations: a systematic review and meta-analysis [0.03%]
药物转运多态性对洋地黄毒苷血药浓度影响的系统评价和meta分析研究
Xin Yee Low,Muhammad Danish Badrul Hisham,Jia Wen Lee et al.
Xin Yee Low et al.
Introduction: Polymorphisms in transporter (P-gp, OATP) genes affect digoxin pharmacokinetics and are crucial for predicting toxicity due to its narrow therapeutic index. However, evidence regarding their effects on digox...
Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes [0.03%]
癌症患者二氢嘧啶脱氢酶(DPYD)基因检测与氟尿嘧啶类药物治疗及预后关系研究
Christopher Rosso,Michela Febbraro,Ioannis A Voutsadakis
Christopher Rosso
Background: Fluoropyrimidines are among the most useful drugs in oncology with an established record of efficacy and safety. A minority of oncology patients bear genetic variants with reduced activity of the main enzyme c...